Genetic deficiency of short-chain acyl-coenzyme A (CoA) dehydrogenase activity was demonstrated in cultured fibroblasts from a 2-yr-old female whose early postnatal life was complicated by poor feeding, emesis, and failure to thrive. She demonstrated progressive skeletal muscle weakness and developmental delay. Her plasma total carnitine level (35 nmol/ml) was low-normal, but was esterified to an abnormal degree (55% vs. controls of < 10%). Her skeletal muscle total carnitine level was low (7.6 nmol/mg protein vs. controls of 14±2 nmol/mg protein) and was 75% esterified. Mild lipid deposition was noted in type I muscle fibers. Fibroblasts from this patient had 50% of control levels of acyl-CoA dehydrogenase activity towards butyryl-CoA as substrate at a concentration of 50 ,M in a fluorometric assay based on the reduction of electron transfer flavoprotein. All of this residual activity was inhibited by an antibody against medium-chain acyl-CoA dehydrogenase. These data demonstrated that medium-chain acylCoA dehydrogenase accounted for 50% of the activity towards the short-chain substrate, butyryl-CoA, under these conditions, but that antibody against that enzyme could be used to unmask the specific and virtually complete deficiency of shortchain acyl-CoA dehydrogenase in this patient. Fibroblasts from her parents had intermediate levels of activity towards butyryl-CoA, consistent with the autosomal recessive inheritance of this metabolic defect.
Introduction
Within the last few years, inherited disorders of enzymes involved in the (3-oxidation of fatty acids have been described by a number of investigators. These enzymatic defects: carnitine palmityltransferase deficiency (1), long-chain acyl-coenzyme 1. Abbreviations used in this paper: CoA, coenzyme A; ETF, electron transfer flavoprotein; LCAD, long-chain acyl-CoA dehydrogenase; MCAD, medium-chain acyl-CoA dehydrogenase; SCAD, short-chain acyl-CoA dehydrogenase. chain acyl-CoA dehydrogenase (MCAD) deficiency (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , electron transfer flavoprotein (ETF) deficiency (14-16), and ETF dehydrogenase deficiency (14) all have been demonstrated in cultured skin fibroblasts, although extracts of other tissues have been used to diagnose specific enzyme defects in this metabolic pathway, including skeletal muscle (1) , liver (4, 9) , and peripheral mononuclear leukocytes (2, 6) .
Under physiological conditions, fatty acids are imported into mitochondria through the action of carnitine palmityltransferase, and then they are oxidized and shortened by a sequence of enzymes in the ,3-oxidation spiral. The first reaction of each (-oxidation spiral is catalyzed by an acyl-CoA dehydrogenase. Three acyl-CoA dehydrogenases are known to act on acyl-CoA esters of different chain length: LCAD, MCAD, and SCAD (17, 18) . These acyl-CoA dehydrogenases are all homotetrameric flavoproteins, and require ETF as an obligatory electron acceptor. Their names indicate the approximate range of chain length of their preferred substrates, but overlap in their substrate specificities has been observed (17, 18) .
The most common genetic disorder of this pathway, MCAD deficiency, has now been confirmed by enzyme measurements or strongly suspected by urinary metabolite excretion patterns in at least 65 patients (3-13; Hale, D. E., and P. M. Coates, unpublished observations).
Patients with LCAD deficiency have some clinical and laboratory findings similar to those with MCAD deficiency, and in addition, may have severe skeletal muscle weakness and cardiomyopathy (2, 19) . Both LCAD deficiency and MCAD deficiency are inherited in an autosomal recessive manner; fibroblasts and leukocytes from parents of affected children have half-normal levels of the affected enzyme (2, 6) .
Recently, short-chain acyl-CoA dehydrogenase (SCAD) deficiency has been identified in four patients (20) (21) (22) . In one of these, Turnbull et al. (20) Antibodies to rat liver medium-chain and short-chain acyl-CoA dehydrogenases. Antibodies were raised in rabbits against purified rat liver MCAD and SCAD, as previously described (17, 23) . These antibodies were monospecific; they did not cross-react with nor inhibit the activity of any rat liver acyl-CoA dehydrogenase other than the one used as antigen (17) . They did, however, cross-react specifically with the corresponding human fibroblast MCAD and SCAD (18, 23, 27) . When used to inhibit acyl-CoA dehydrogenase activities, they were preincubated with cell extracts for 1 h at room temperature before assay. Because the acyl-CoA dehydrogenase enzymes lose -25% of their activity per hour under these conditions without the addition of antibody (28), a control was included in which the same cell extract was incubated at room temperature for 1 h with nonimmune serum.
Results
SCAD activity has been measured in this and in previous studies using butyryl-CoA as substrate. As shown in Table I 4 .14±0.38 nmol ETF reduced/min per mg protein, P < 0.01), when assayed using the same method. This suggests that a substantial portion of the activity towards the short-chain substrate under the assay conditions described, with ETF as the electron acceptor, is due to MCAD. Thus, if 50% of the measured activity towards bgiityryl-CoA can be accounted for by MCAD, then the SCAD enzyme will contribute, at most, 50% of the apparent enzyme activity when assayed with this substrate. Second, fibroblasts from both parents of this patient with SCAD deficiency had -75% of control enzyme activity using butyryl-CoA as substrate (Table I) 
The combination of 75% residual activity towards butyrylCoA and normal activity towards octanoyl-CoA distinguishes heterozygotes for SCAD deficiency from heterozygotes for MCAD deficiency, who also had -75% of control activity towards butyryl-CoA, but whose activity towards octanoylCoA was only 50% of control levels (6).
Third, we have shown elsewhere (Hale, D. E., G. Finocchiaro, P. M. Coates, and K. Tanaka, manuscript in preparation) that an antibody raised against MCAD (anti-MCAD) inhibited virtually all of the enzyme activity towards octanoylCoA and inhibited 50% of the enzyme activity towards butyryl-CoA in control cells; it was without effect on the residual enzyme activity towards butyryl-CoA in MCAD-deficient cells.
In the present study, an antibody raised against SCAD (anti-SCAD) was found to inhibit 50% of the enzyme activity towards butyryl-CoA in control cells and to completely inhibit the residual activity towards butyryl-CoA in MCAD-deficient cells (Table II) . The residual activity towards butyryl-CoA as substrate in cells from G-I was unaffected by anti-SCAD (92% of activity present in cells treated with nonimmune IgG, P > 0.1), but it was almost completely inhibited by anti-MCAD (10% of activity present in cells treated with nonimmune IgG, P < 0.05). These data support the conclusion that proband G-1 has a specific SCAD deficiency and that the residual 51% of Finally, we have measured acyl-CoA dehydrogenase activities in fibroblasts from the patient described by Turnbull et al. (20) with short-chain acyl-CoA dehydrogenase deficiency demonstrated in skeletal muscle. Acyl-CoA dehydrogenase activities towards butyryl-CoA, octanoyl-CoA, and palmitylCoA were 2.12, 4.34, and 2.04 nmol ETF reduced/min per mg protein, respectively. We also measured these enzymes in fibroblasts from the patient described by Bennett et al. (28) with a defect in fibroblast short-chain fatty acid oxidation. AcylCoA dehydrogenase activities towards butyryl-CoA, octanoylCoA, and palmityl-CoA were 2.16, 4.37, and 1.93 nmol ETF reduced min per mg protein, respectively. Neither patient had a SCAD deficiency that was evident in fibroblasts. Discussion Short-chain acyl-CoA dehydrogenase deficiency has been described recently in association with distinctly different clinical phenotypes. The patient described in the present report presented early in life with nonspecific vomiting, poor feeding, and failure to thrive. Her chronic problems were largely those of progressive skeletal muscle weakness and developmental delay. Her findings are very different from those of the two female infants with SCAD deficiency identified in cultured fibroblasts by Amendt et al. (22) . They both presented in early infancy with poor feeding and lethargy, significant metabolic acidosis, and excreted a number of metabolites in urine, suggestive of a block in short-chain fatty acid oxidation. Their metabolite excretion pattern resembled that of a patient described by Bennett et al. (28), who had a defect in short-chain fatty acid oxidation. This latter patient, however, was demonstrated in the present report not to have SCAD deficiency; it is possible that another enzyme in 3-oxidation is defective in her cells.
The patients described with muscle SCAD deficiency (20, 21) had significant skeletal muscle weakness, myoglobinuria, and muscle carnitine deficiency, with no findings referable to an abnormality in hepatic fatty acid metabolism. In some respects, these patients resembled others who had been reported previously with "muscle carnitine deficiency" (29). These patients (20, 21) There are several possible explanations for the apparent tissue difference in the expression of SCAD deficiency in the patient reported by Turnbull et al. (20) . One possible explanation is a mutation of a muscle-specific SCAD isozyme; this assumes that there are tissue-specific SCAD isozymes. Carroll et al. (30) recently used an electrophoretic analysis coupled with a histochemical staining method to demonstrated acylCoA dehydrogenases in crude extracts of human skeletal muscle mitochondria. MCAD and LCAD in skeletal muscle were identical to their counterparts in liver and heart. By contrast, SCAD was detected only in muscle, and not in heart or liver under these conditions. More recently, Finocchiaro et al. (18) purified SCAD, MCAD, and isovaleryl-CoA dehydrogenase to homogeneity from human liver. In general, these human liver acyl-CoA dehydrogenases were identical to their counterparts in human fibroblasts (23, 27) and placenta (Finocchiaro, G., M. Ito, and K. Tanaka, unpublished observations), and were Short-Chain Acyl-Coenzyme A Dehydrogenase Deficiency 173 very similar to the corresponding rat enzymes in their molecular, catalytic, and immunologic properties (17, 18) . Current evidence, therefore, seems to suggest that a muscle-specific SCAD isozyme is unlikely, but at present, there are no direct data that conclusively exclude this possibility. It is possible that all tissues share the same SCAD gene, but that the mechanisms that regulate its expression may differ among them. Alternatively, the apparent SCAD deficiency in this patient's cells may be a secondary phenomenon, perhaps due to degeneration of muscle mitochondria for other reasons. Another possibility that may explain her enzyme abnormality is a riboflavin-responsive multiple acyl-CoA dehydrogenation defect (31) . SCAD is relatively susceptible to riboflavin deficiency, at least in the rat (32, 33) . This patient might be sufficiently riboflavin deficient to depress SCAD activity in muscle without affecting the activities of other acyl-CoA dehydrogenases; her cultured fibroblasts may have normal SCAD activity because the medium in which they are grown contains riboflavin.
The clinical and laboratory findings in patient G-l, which include chronic skeletal muscle weakness, developmental delay, and reduced muscle carnitine levels with an increased content of esterified carnitine, are different from those often found in patients with MCAD or LCAD deficiency. Many of the latter patients present during the first 18 mo of life with a Reye Syndrome-like episode, in which fasting stress results in lethargy and vomiting, sometimes leading to coma and often associated with hypoglycemia, a failure of ketosis and secondary plasma and tissue carnitine deficiency (19) . Only the rare patient with MCAD deficiency has been reported to have muscle weakness, whereas this has been a common finding among patients with LCAD deficiency.
Over the last several years, there has developed a simple strategy for defining patients with carnitine deficiency (29): those with low levels of carnitine in plasma, liver, and muscle have been identified as having "systemic carnitine deficiency," whereas those with low muscle carnitine levels, but normal plasma and liver carnitine, were said to have "muscle carnitine deficiency." In general, the latter disease is characterized by low muscle carnitine levels, progressive muscle weakness (of varying degree), and lipid accumulation in skeletal muscle fibers (also of varying degree). These patients usually have been identified at a much older age than G-1 (for example, the patient described by Turnbull et al. [20] ), although a few have presented within the first several years of life. For some of them, the clinical course has been unrelenting and fatal in spite of carnitine therapy, whereas others have responded favorably to oral carnitine therapy (29). It is unknown whether any of these patients have SCAD deficiency, either expressed in muscle, as in Turnbull's patient, or perhaps generalized and expressed in fibroblasts, as in patient G-1. Together, however, these findings suggest that patients who have until now carried the diagnosis of muscle carnitine deficiency should be reevaluated to determine whether they have specific defects in ,8-oxidation, such as SCAD deficiency.
We can speculate that, by analogy with other known de- 
